You might also like:
News & Opinion
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1
In the media
Tim Guilliams talks about Using AI to De-Risk Rare Disease Drug Development

News & Opinion
Jonathan Milner, Ph.D., Appointed as Non-Executive Chairman of Healx